Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 19010331 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Doggen K, et al. (2009) Ventricular ErbB2/ErbB4 activation and downstream signaling in pacing-induced heart failure. J Mol Cell Cardiol 46, 33-8 19010331
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S473-p - Akt1 (human)
Orthologous residues
Akt1 (human): S473‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  heart
 Cellular systems studied:  tissue
 Species studied:  dog, rat
 Comments:  left ventricular tissue
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
heart failure decrease
neuregulin increase

Y467-p - PIK3R1 (human)
Orthologous residues
PIK3R1 (human): Y467‑p, PIK3R1 (mouse): Y467‑p, PIK3R1 (rat): Y467‑p, PIK3R1 (cow): Y467‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  heart
 Cellular systems studied:  tissue
 Species studied:  dog, rat
 Comments:  left ventricular tissue
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
heart failure increase

T203-p - ERK1 (rat)
Orthologous residues
ERK1 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  heart
 Cellular systems studied:  tissue
 Species studied:  dog, rat
 Comments:  left ventricular tissue
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
heart failure decrease
neuregulin increase

Y205-p - ERK1 (rat)
Orthologous residues
ERK1 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  heart
 Cellular systems studied:  tissue
 Species studied:  dog, rat
 Comments:  left ventricular tissue
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
heart failure decrease
neuregulin increase

T183-p - ERK2 (rat)
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  heart
 Cellular systems studied:  tissue
 Species studied:  dog, rat
 Comments:  left ventricular tissue
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
heart failure decrease
neuregulin increase

Y185-p - ERK2 (rat)
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  heart
 Cellular systems studied:  tissue
 Species studied:  dog, rat
 Comments:  left ventricular tissue
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
heart failure decrease
neuregulin increase

Y879-p - HER2 (rat)
Orthologous residues
HER2 (human): Y877‑p, HER2 iso2 (human): Y267‑p, HER2 (mouse): Y878‑p, HER2 (rat): Y879‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  heart
 Cellular systems studied:  tissue
 Species studied:  dog, rat
 Comments:  left ventricular tissue
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
heart failure increase

Y1250-p - HER2 (rat)
Orthologous residues
HER2 (human): Y1248‑p, HER2 iso2 (human): Y638‑p, HER2 (mouse): Y1249‑p, HER2 (rat): Y1250‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  heart
 Cellular systems studied:  tissue
 Species studied:  dog, rat
 Comments:  left ventricular tissue
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
heart failure increase
neuregulin increase

Y1284-p - HER4 (rat)
Orthologous residues
HER4 (human): Y1284‑p, HER4 iso2 (human): Y1274‑p, HER4 iso3 (human): Y1268‑p, HER4 iso4 (human): Y1258‑p, HER4 (mouse): Y1284‑p, HER4 (rat): Y1284‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  heart
 Cellular systems studied:  tissue
 Species studied:  dog, rat
 Comments:  left ventricular tissue
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
heart failure increase
neuregulin increase


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.